Objectives: To determine prognostic factors for the Health Assessment Questionnaire-Disability Index (HAQ-DI) progression in patients with rheumatoid arthritis (RA) in clinical practice.
Methods: We evaluated 388 biological disease-modifying anti-rheumatic drug (bDMARD)-naïve Japanese patients with RA with moderate to high disease activity at study entry after being treated with conventional synthetic DMARDs. These patients were treated according to a treat-to-target (T2T) strategy for one year. The Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) and the HAQ-DI were assessed every three months. We also evaluated joint destruction using a modified total Sharp score at baseline and at one year. HAQ-DI progression was defined as the yearly progression of HAQ-DI >0.1. We performed a multiple logistic regression analysis to explore the factors predicting HAQ-DI progression at one year.
Results: HAQ-DI progression was observed in 18% of the patients. The multiple logistic regression analysis revealed the independent variables associated with HAQ-DI progression were: DAS28-ESR >5.1 at baseline (odds ratio [OR] 0.31, 95% con dence interval [CI] 0.13-0.74, p=0.0083); HAQ-DI score at baseline <0.5 (OR 2.27, 95% CI 1.22-4.26, p=0.0102); and achievement of low disease activity at 12 weeks (OR 0.42, 95% CI 0.21-0.82, p=0.0112).
Conclusions: Our data suggest that maintaining clinical improvement according to T2T and initiating the treatment at an early stage are important for functional improvement after one year and that patients with low baseline HAQ scores have a higher risk of HAQ disability progression.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
High-Titer Rheumatoid Factor is Associated with Worse Clinical Outcomes and Higher Needs for Advanced Therapies in Rheumatoid Arthritis Under Real-Life Conditions.
Rheumatol Ther
December 2024
Universidade Do Estado Do Rio de Janeiro, Rheumatology, Rio de Janeiro, Brazil.
Article Synopsis
- RF titers are significant in the pathophysiology of rheumatoid arthritis (RA) and vary in their clinical impact, with high RF titers linked to poorer health outcomes.
- A study with 1,097 RA adults found a substantial portion had positive RF, with high titers prevalent, and identified associations of high RF with factors such as tobacco use and higher body mass index.
- High RF levels correlated with increased disease activity, reduced functional capacity, and greater use of corticosteroids and biological drugs, indicating a need for careful monitoring in RA patients.
A prospective randomized-controlled non-blinded comparative study of the JAK inhibitor (baricitinib) with TNF-α inhibitors and conventional DMARDs in a sample of Egyptian rheumatoid arthritis patients.
Clin Rheumatol
December 2024
Rheumatology and Rehabilitation Department, Faculty of Medicine, Sohag University, Sohag, Egypt.
To evaluate the efficacy of baricitinib compared to TNF-α Inhibitors and conventional DMARDs (cDMARDs) in patients with RA. Our study included 334 RA patients classified into 3 groups: the first receiving baricitinib, the second receiving TNF-α Inhibitors, and the third receiving cDMARDs. Patients were evaluated at baseline, week 12, and week 24 using TJC, SJC, VAS, DAS28, CDAI, and HAQ-DI.
View Article and Find Full Text PDFRelationship Between Serum Interleukin-6 Levels, Systemic Immune-Inflammation Index, and Other Biomarkers Across Different Rheumatoid Arthritis Severity Levels.
Cureus
October 2024
Pharmacology and Therapeutics, Peshawar Medical and Dental College, Peshawar, PAK.
Background Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation, pain, and progressive disability. Identifying biomarkers that accurately reflect disease severity is crucial for effective management. Interleukin-6 (IL-6) is a pro-inflammatory cytokine involved in the pathogenesis of RA, and the systemic immune-inflammation index (SII) is emerging as a useful marker of systemic inflammation.
View Article and Find Full Text PDFUpadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial.
Trials
September 2024
The Department of Rheumatology, Guangdong Provincial Second Hospital of Traditional Chinese Medicine, Guangzhou, China.
Article Synopsis
- Psoriatic arthritis (PsA) patients often deal with anxiety, and while upadacitinib is effective for PsA symptoms, its effect on anxiety requires more research.* -
- A 12-week trial assigned PsA patients with anxiety either to upadacitinib (15 mg daily) or adalimumab (40 mg every 2 weeks) to measure changes in anxiety and other health indicators.* -
- The study aims to clarify upadacitinib's impact on anxiety in PsA patients and highlight the necessity of managing anxiety alongside physical symptoms during treatment.*
Predictors of clinical features in early-onset severe systemic sclerosis: An analysis from a multicenter prospective observational Japanese cohort.
J Dermatol
October 2024
Department of Dermatology, University of Fukui, Fukui, Japan.
Article Synopsis
- The study investigates prognostic indicators in Japanese patients with early-stage systemic sclerosis (SSc) to predict disease progression, particularly focusing on those with diffuse cutaneous involvement and/or interstitial lung disease.
- Researchers assessed clinical and laboratory parameters in a cohort of 115 patients followed for 4 years, analyzing correlations between baseline measurements and outcomes.
- Key findings suggest that certain factors, such as finger-to-palm distance and the presence of anti-topoisomerase I antibodies, can help anticipate disease progression, but further research with larger samples is necessary for validation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!